|
|
Article: Celltech, BMS Stop Development Of NSCLC Product After Phase II.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Celltech Group plc's partner, Bristol-Myers Squibb Co., has decided against further development of a high-risk product in non-small-cell lung cancer following disappointing interim analysis of a Phase II study.
The product is a selective matrix metalloproteinase inhibitor referred to by the companies as BMS-275291.
On Monday Celltech released news saying the Drug Safety Monitoring Committee reported that BMS-275291 was not likely to meet its predetermined efficacy endpoint. The candidate, developed by Celltech, of Slough, UK, was being evaluated in combination with Taxol (paclitaxel) and Paraplatin (carboplatin). Celltech had ...
Related newspaper, magazine, and journal articles:
|